Income Statement Guided Therapeutics, Inc.
Stocks
GTHP
US40171F5017
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2290 USD | -.--% |
|
-18.19% | -57.59% |
| 07-14 | Guided Therapeutics, Inc. Announces New Agreement With Yuanshuo Medical Instruments Corporation | CI |
| 06-16 | Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 81K | 13K | 98K | 7K | 767K | |||||
Total Revenues | 81K | 13K | 98K | 7K | 767K | |||||
Cost of Goods Sold, Total | 61K | 81K | 62K | 5K | 196K | |||||
Gross Profit | 20K | -68K | 36K | 2K | 571K | |||||
Selling General & Admin Expenses, Total | 2.31M | 3.19M | 3.26M | 1.58M | 2.47M | |||||
R&D Expenses | 69K | 77K | 228K | 526K | 469K | |||||
Other Operating Expenses, Total | 2.38M | 3.26M | 3.49M | 2.11M | 2.94M | |||||
Operating Income | -2.36M | -3.33M | -3.46M | -2.11M | -2.37M | |||||
Interest Expense, Total | -1.15M | -582K | -278K | -381K | -617K | |||||
Interest And Investment Income | - | - | 6K | 3K | - | |||||
Net Interest Expenses | -1.15M | -582K | -272K | -378K | -617K | |||||
Other Non Operating Income (Expenses) | 864K | 43K | 44K | 0 | 230K | |||||
EBT, Excl. Unusual Items | -2.65M | -3.87M | -3.68M | -2.49M | -2.76M | |||||
Other Unusual Items | 578K | -469K | 196K | 69K | -437K | |||||
EBT, Incl. Unusual Items | -2.07M | -4.34M | -3.49M | -2.42M | -3.2M | |||||
Earnings From Continuing Operations | -2.07M | -4.34M | -3.49M | -2.42M | -3.2M | |||||
Net Income to Company | -2.07M | -4.34M | -3.49M | -2.42M | -3.2M | |||||
Net Income - (IS) | -2.07M | -4.34M | -3.49M | -2.42M | -3.2M | |||||
Preferred Dividend and Other Adjustments | 361K | 631K | 270K | 174K | 150K | |||||
Net Income to Common Incl Extra Items | -2.43M | -4.97M | -3.76M | -2.59M | -3.35M | |||||
Net Income to Common Excl. Extra Items | -2.43M | -4.97M | -3.76M | -2.59M | -3.35M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.18 | -0.15 | -0.07 | -0.05 | -0.04 | |||||
Basic EPS - Continuing Operations | -0.18 | -0.15 | -0.07 | -0.05 | -0.04 | |||||
Basic Weighted Average Shares Outstanding | 13.38M | 32.5M | 51.13M | 57.34M | 78.41M | |||||
Net EPS - Diluted | -0.18 | -0.15 | -0.07 | -0.05 | -0.04 | |||||
Diluted EPS - Continuing Operations | -0.18 | -0.15 | -0.07 | -0.05 | -0.04 | |||||
Diluted Weighted Average Shares Outstanding | 13.38M | 32.5M | 51.13M | 57.34M | 78.41M | |||||
Normalized Basic EPS | -0.12 | -0.07 | -0.05 | -0.03 | -0.02 | |||||
Normalized Diluted EPS | -0.12 | -0.07 | -0.05 | -0.03 | -0.02 | |||||
Supplemental Items | ||||||||||
EBITDA | -2.36M | -3.33M | -3.45M | -2.1M | -2.36M | |||||
EBITA | -2.36M | -3.33M | -3.46M | -2.11M | -2.37M | |||||
EBIT | -2.36M | -3.33M | -3.46M | -2.11M | -2.37M | |||||
EBITDAR | - | - | - | - | -2.35M | |||||
Normalized Net Income | -1.66M | -2.42M | -2.3M | -1.55M | -1.72M | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 141K | 181K | 268K | 287K | 169K | |||||
General and Administrative Expenses | 2.17M | 3.01M | 3M | 1.3M | 2.29M | |||||
Research And Development Expense From Footnotes | 69K | 77K | 228K | 526K | 469K | |||||
Net Rental Expense, Total | - | - | - | - | 12.9K | |||||
Imputed Operating Lease Interest Expense | - | - | - | - | 24.98K | |||||
Imputed Operating Lease Depreciation | - | - | - | - | -12.08K | |||||
Stock-Based Comp., G&A Exp. (Total) | 664K | 1.2M | 739K | - | 297K | |||||
Stock-Based Comp., Other (Total) | 228K | 176K | 1.07M | 120K | 80.19K | |||||
Total Stock-Based Compensation | 892K | 1.38M | 1.81M | 120K | 377K |
- Stock Market
- Stocks
- GTHP Stock
- Financials Guided Therapeutics, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















